Gufic Biosciences is currently trading at Rs. 350.00, up by 15.10 points or 4.51% from its previous closing of Rs. 334.90 on the BSE.
The scrip opened at Rs. 334.95 and has touched a high and low of Rs. 354.25 and Rs. 334.95 respectively. So far 12343 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 409.00 on 01-Aug-2025 and a 52 week low of Rs. 267.50 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 354.25 and Rs. 274.00 respectively. The current market cap of the company is Rs. 3437.18 crore.
The promoters holding in the company stood at 72.50%, while Institutions and Non-Institutions held 4.25% and 23.25% respectively.
Gufic Biosciences has received approval to make further investment in the equity share capital of Saraswat Co-operative Bank by way of subscription to 57,50,800 equity shares having face value of Rs 10 each aggregating to Rs 5.75 crore. The company regularly avails various banking and credit facilities from Saraswat Bank for its business operations and expansion requirements.
The proposed subscription to additional equity shares of the Bank is being undertaken in line with the existing banking relationship and credit exposure of the company and is expected to strengthen the company’s banking relationship with the Bank. The investment is also intended as part of the company’s broader investment and treasury management strategy and may provide potential long-term benefits by way of investment appreciation, dividend income and improved banking engagement.
The Board of Directors of the Company at its meeting held on May 29, 2026, has approved the same.
Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1783.55 |
| Dr. Reddys Lab | 1277.80 |
| Cipla | 1400.70 |
| Zydus Lifesciences | 1088.90 |
| Lupin | 2268.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: